Evasive maneuvers by hepatitits C virus

Hepatology

Volumn 38, Issue 3, 2003, Pages 769-771

  Lindenbach, Brett D ^a   Rice, Charles M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEOMYCIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ENZYME STRUCTURE; HEPATITIS C; HEPATITIS C VIRUS; NOTE; PRIORITY JOURNAL; REPLICON; SEQUENCE ANALYSIS; VIRUS REPLICATION;

EID: 0041821999     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0270-9139(03)81302-2     Document Type: Note

References (26)

1. Holland JJ, Domingo E, de la Torre JC, Steinhauer DA. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol 1990;64:3960-3962.
2. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992;66:3225-3229.
3. Eigen M, Schuster P. The hypercycle. A principle of natural natural self-organization. Berlin, Heidelberg, New York: Springer-Verlag, 1979:92.
4. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. HEPATOLOGY 2002;36(Suppl 1):S121-S127.
5. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
6. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000;68:556-567.
7. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. HEPATOLOGY 2002; 35:1002-1009.
8. Crorty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001;98:6895-6900.
9. Lindenbach BD, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. Volume 1. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001;991-1041.
10. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997;277:570-574.
11. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
12. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000;290:1972-1974.
13. Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001;75:8516-8523.
14. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001;75: 4614-4624.
15. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001; 75:1437-1449.
16. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87: 343-355.
17. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996;87:331-342.
18. Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, Steinkuehler C, et al. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 1998;7:837-847.
19. Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure Fold Des 1999; 7:1353-1363.
20. Urbani A, Bianchi E, Narjes F, Tramontano A, De Francesco R, Steinkuhler C, Pessi A. Substrate specificity of the hepatitis C virus serine protease NS3. J Biol Chem 1997;272:9204-9209.
21. Zhang R, Durkin J, Windsor WT, McNemar C, Ramanathan L, Le HV. Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J Virol 1997;71:6208-6213.
22. Llinas-Brunet M, Bailey M, Fazal G, Goulet S, Halmos T, Laplante S, Maurice R, et al. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett 1998;8:1713-1718.
23. Steinkuhler C, Biasiol G, Brunetti M, Urbani A, Koch U, Cortese R, Pessi A, et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 1998;37:8899-8905.
24. Tsantrizos YS, Bolger G, Bonneau P, Cameron DR, Goudreau N, Kukolj G, LaPlante SR, et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew Chem Int Ed Engl 2003;42:1356-1360.
25. Bukh J, Pietschmann T, Lohmann V, Krieger N, Faulk K, Engle RE, Govindarajan S, et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci U S A 2002;99:14416-14421.
26. Narjes F, Koch U, Steinkuhler C. Recent developments in the discovery of hepatitis C virus serine protease inhibitors - towards a new class of antiviral agents? Expert Opin Investig Drugs 2003;12:153-163.